Skip to main content
Fig. 5 | BMC Immunology

Fig. 5

From: The correlation of EZH2 expression with the progression and prognosis of hepatocellular carcinoma

Fig. 5

EZH2 expression levels in LIHC. A LIHC and healthy samples from the GEPIA database; B EZH2 expression in diverse liver hepatocellular carcinoma stages in the GEPIA database; C EZH2 levels within diverse LIHC molecular subtypes derived from the TISIDB database; D EZH2 expression within diverse LIHC immune subtypes in the TISIDB database; E EZH2 protein expression within LIHC samples in relation to healthy samples in the Human Protein Atlas data. T: EZH2 protein expression within cancer samples (quantity: 75–25%; intensity: strong; staining: high) https://www.proteinatlas.org/ENSG00000106462-EZH2/pathology/liver+cancer#img; N: Protein levels of EZH2 in normal tissue (staining: Not detected; intensity: weak, quantity: < 25%) https://www.proteinatlas.org/ENSG00000106462-EZH2/tissue/liver#img;

Back to article page